Cue Biopharma jumps as investors react to Ascendant-221 licensing deal and fresh financing news

Cue Biopharma (CUE) is up 87.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is investor excitement around Cue’s newly announced exclusive license for Ascendant-221, a clinical-stage anti-IgE antibody program that expands the company’s allergy pipeline. The move may have been amplified by recent capital markets activity and a recently completed reverse stock split, which can increase volatility in small-cap biotech trading.

Details:

Cue announced an exclusive license agreement with Ascendant Health Sciences for Ascendant-221, described as a clinical-stage dual-mechanism anti-IgE monoclonal antibody aimed at allergic diseases.

The company highlighted a Phase 2 study in chronic spontaneous urticaria (CSU) being run by Ascendant Health and discussed plans to initiate a global Phase 2b trial in food allergy.

Cue also announced a $30 million private placement, including the issuance of shares and warrants (including pre-funded warrants) and a commitment to file a resale registration statement.

In late April, Cue disclosed a 1-for-30 reverse stock split effective April 23, 2026, which can mechanically change share count and contribute to larger percentage swings.

Sources:

GlobeNewswire, U.S. Securities and Exchange Commission, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CUE Insider Trading Activity

$CUE insiders have traded $CUE stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CUE stock by insiders over the last 6 months:

PASHA SARRAF has made 5 purchases buying 323,857 shares for an estimated $99,747 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$CUE Hedge Fund Activity

We have seen 15 institutional investors add shares of $CUE stock to their portfolio, and 27 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

LION POINT CAPITAL, LP added 2,202,854 shares (+inf%) to their portfolio in Q4 2025, for an estimated $672,751
GC WEALTH MANAGEMENT RIA, LLC added 1,200,000 shares (+35.0%) to their portfolio in Q4 2025, for an estimated $366,480
ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC removed 462,550 shares (-96.7%) from their portfolio in Q1 2026, for an estimated $3,190,207
TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC added 407,568 shares (+1231.2%) to their portfolio in Q4 2025, for an estimated $124,471
ANGELES WEALTH MANAGEMENT, LLC added 190,000 shares (+158.3%) to their portfolio in Q4 2025, for an estimated $58,026
UBS GROUP AG removed 152,310 shares (-76.5%) from their portfolio in Q4 2025, for an estimated $46,515
BANK OF AMERICA CORP /DE/ removed 116,952 shares (-36.0%) from their portfolio in Q4 2025, for an estimated $35,717

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.